within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BA02_Procainamide;

model Procainamide_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.83,
    Cl = 7.35e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004966666666666666,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Procainamide_1</td></tr><tr><td>ATC code:</td><td>C01BA02_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.3</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Procainamide is a Class Ia antiarrhythmic drug used to treat and prevent various types of cardiac arrhythmias, including ventricular and supraventricular arrhythmias. It acts by blocking sodium channels in the heart. Procainamide is approved and still in clinical use, though less frequently than in the past due to alternative therapies and concerns regarding side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult healthy volunteers after oral administration.</p><h4>References</h4><ol><li><p>Klotz, U (2007). Antiarrhythmics: elimination and dosage considerations in hepatic impairment. <i>Clinical pharmacokinetics</i> 46(12) 985–996. DOI:<a href=\"https://doi.org/10.2165/00003088-200746120-00002\">10.2165/00003088-200746120-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18027986/\">https://pubmed.ncbi.nlm.nih.gov/18027986</a></p></li><li><p>Chow, MS, et al., &amp; Hilleman, D (1988). Propafenone: a new antiarrhythmic agent. <i>Clinical pharmacy</i> 7(12) 869–877. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3061720/\">https://pubmed.ncbi.nlm.nih.gov/3061720</a></p></li><li><p>Koup, JR, et al., &amp; de Vries, TM (1998). Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets. <i>Therapeutic drug monitoring</i> 20(1) 73–77. DOI:<a href=\"https://doi.org/10.1097/00007691-199802000-00014\">10.1097/00007691-199802000-00014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9485559/\">https://pubmed.ncbi.nlm.nih.gov/9485559</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01BA02_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Procainamide_1;
